Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015		Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 348,192	[1]	$ 96,907	[1]
Accounts receivable, net	19,064	[1]	19,969	[1]
Inventory, net	18,324	[1]	16,604	[1]
Prepaid expenses and other current assets	8,445	[1]	9,389	[1]
Total current assets	394,025	[1]	142,869	[1]
Property, plant, equipment, and investment properties, net	15,120	[1]	16,411	[1]
Intangible assets, net	59,432	[1]	62,649	[1]
In-process research and development	793,000	[1]	793,152	[1]
Goodwill	223,219	[1]	224,292	[1]
Investments, net	22,380	[1]	22,453	[1]
Other assets	5,073	[1]	5,838	[1]
Total assets	1,512,249	[1]	1,267,664	[1]
Current liabilities:
Accounts payable	10,472	[1]	8,744	[1]
Accrued expenses	158,763	[1]	60,912	[1]
Current portion of lines of credit and notes payable	13,603	[1]	13,455	[1]
Total current liabilities	182,838	[1]	83,111	[1]
2033 Senior Notes, net of discount and estimated fair value of embedded derivatives	106,673	[1]	131,454	[1]
Other long-term liabilities, principally deferred revenue and deferred tax liabilities	410,165	[1]	217,358	[1]
Total long-term liabilities	516,838	[1]	348,812	[1]
Total liabilities	699,676	[1]	431,923	[1]
Equity:
Common Stock - $0.01 par value, 750,000,000 shares authorized; 459,314,572 and 433,421,677 shares issued at March 31, 2015 and December 31, 2014, respectively	4,593	[1]	4,334	[1]
Treasury Stock - 1,245,367 and 1,245,367 shares at March 31, 2015 and December 31, 2014, respectively	(4,051)	[1]	(4,051)	[1]
Additional paid-in capital	1,628,818	[1]	1,529,096	[1]
Accumulated other comprehensive income (loss)	(17,503)	[1]	(12,392)	[1]
Accumulated deficit	(791,955)	[1]	(674,843)	[1]
Total shareholders’ equity attributable to OPKO	819,902	[1]	842,144	[1]
Noncontrolling interests	(7,329)	[1]	(6,403)	[1]
Total shareholders’ equity	812,573	[1]	835,741	[1]
Total liabilities and equity	$ 1,512,249	[1]	$ 1,267,664	[1]

[1] As of March 31, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.1 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.